Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN HIVES RELIEF versus TEMARIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN HIVES RELIEF versus TEMARIL.
CLARITIN HIVES RELIEF vs TEMARIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inverse agonist at histamine H1 receptors, blocking histamine-mediated effects in allergic reactions.
Temaril (trimeprazine tartrate and prednisolone) combines an antipruritic phenothiazine antihistamine with a corticosteroid. Trimeprazine blocks histamine H1 receptors, reducing pruritus and allergic reactions. Prednisolone suppresses inflammation via glucocorticoid receptor activation, inhibiting phospholipase A2 and cytokine production.
10 mg orally once daily
2.5 mg orally twice daily or 5 mg orally at bedtime; maximum 10 mg/day.
None Documented
None Documented
8.4 hours (range 3-20 hours) for loratadine; 28 hours (range 8.8-92 hours) for active metabolite desloratadine, allowing once-daily dosing.
Terminal elimination half-life is 9–12 hours in adults; prolonged in hepatic impairment (up to 20 hours). Given TID dosing, steady state is reached within 2 days.
Renal: ~40% as metabolites, <1% unchanged; Fecal: ~40%; Biliary: minor contribution.
Primarily via kidneys as metabolites; unchanged drug accounts for <1%. Biliary/fecal excretion is minor. Approx. 90% recovered in urine within 24 hours.
Category C
Category C
Antihistamine
Antihistamine